AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study
Status:
Recruiting
Trial end date:
2023-11-25
Target enrollment:
Participant gender:
Summary
This is a phase 1, single dose, randomised, double-blind, two-way crossover study to compare
ultra-rapid-acting concentrated insulin aspart AT278 (U500/mL) with standard insulin aspart
NovoRapid® (U100/mL) in participants with T2D.